Post-translational modifications of Runx1 regulate its activity in the cell

Blood Cells, Molecules, and Diseases

Volumn 43, Issue 1, 2009, Pages 30-34

  Wang, Lan ^a   Huang, Gang ^a   Zhao, Xinyang ^a   Hatlen, Megan A ^a   Vu, Ly ^a   Liu, Fan ^a   Nimer, Stephen D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acetylation; Acetyltransferases; Leukemia; Methylation; Methyltransferases; Transcription

Indexed keywords

ACYLTRANSFERASE; ARGININE; DEPSIPEPTIDE; DNA; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; LYSINE; METHYLTRANSFERASE; PROTEIN ETO; PROTEIN SERINE THREONINE KINASE; TANESPIMYCIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL RENEWAL; DENDRITIC CELL; DNA METHYLATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; HEMATOPOIETIC CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION;

ACETYLTRANSFERASES; ANIMALS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA METHYLATION; HISTONE DEACETYLASES; HUMANS; METHYLTRANSFERASES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 68649116713     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2009.03.005     Document Type: Review

References (59)

1. Canman C.E., et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281 5383 (1998) 1677-1679
2. Ito A., et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21 22 (2002) 6236-6245
3. Frank R., et al. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 11 12 (1995) 2667-2674
4. Uchida H., Zhang J., and Nimer S.D. AML1A and AML1B can transactivate the human IL-3 promoter. J. Immunol. 158 5 (1997) 2251-2258
5. Klampfer L., et al. The AML1/ETO fusion protein activates transcription of BCL-2. Proc. Natl. Acad. Sci. U. S. A. 93 24 (1996) 14059-14064
6. Frank R.C., et al. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1. Oncogene 18 9 (1999) 1701-1710
7. Jakubowiak A., et al. Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J. Biol. Chem. 275 51 (2000) 40282-40287
8. Nimer S.D., and Moore M.A. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells. Oncogene 23 24 (2004) 4249-4254
9. Huang G., et al. PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat. Genet. 40 1 (2008) 51-60
10. Mulloy J.C., et al. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 99 1 (2002) 15-23
11. Mulloy J.C., et al. AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. Proc. Natl. Acad. Sci. U. S. A. 102 11 (2005) 4016-4021
12. Tanaka T., et al. The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol. Cell. Biol. 16 7 (1996) 3967-3979
13. Hamelin V., et al. Thrombopoietin regulates IEX-1 gene expression through ERK-induced AML1 phosphorylation. Blood 107 8 (2006) 3106-3113
14. Imai Y., et al. The corepressor mSin3A regulates phosphorylation-induced activation, intranuclear location, and stability of AML1. Mol. Cell. Biol. 24 3 (2004) 1033-1043
15. Kitabayashi I., et al. Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J. 20 24 (2001) 7184-7196
16. Lutterbach B., et al. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J. Biol. Chem. 275 1 (2000) 651-656
17. Biggs J.R., et al. AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. Mol. Cell. Biol. 26 20 (2006) 7420-7429
18. Ichikawa M., et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat. Med. 10 3 (2004) 299-304
19. Barbetti V., Santini V., et al. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene 27 (2008) 1767-1778
20. Yang G., et al. Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. Oncogene 26 1 (2007) 91-101
21. Tabe Y., et al. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Cell Death Differ. 14 8 (2007) 1443-1456
22. Bernardin-Fried F., et al. AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression. J. Biol. Chem. 279 15 (2004) 15678-15687
23. Zhang L., et al. Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation. Blood 111 3 (2008) 1193-1200
24. Peterson L.F., et al. The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3. Mol. Cell. Biol. 25 23 (2005) 10205-10219
25. Fujimoto T., et al. Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPalpha interaction. EMBO J. 26 9 (2007) 2361-2370
26. Sims III R.J., Nishioka K., and Reinberg D. Histone lysine methylation: a signature for chromatin function. Trends Genet. 19 11 (2003) 629-639
27. Chakraborty S., et al. SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivo. Oncogene 22 34 (2003) 5229-5237
28. Gary J.D., and Clarke S. RNA and protein interactions modulated by protein arginine methylation. Prog. Nucleic Acid Res. Mol. Biol. 61 (1998) 65-131
29. Pawlak M.R., et al. Arginine N-methyltransferase 1 is required for early postimplantation mouse development, but cells deficient in the enzyme are viable. Mol. Cell. Biol. 20 13 (2000) 4859-4869
30. Yamagata K.D.H., Takahashi Y., Namiki K., Hisatake K., Kako K., Mukai H., Kasuya Y., and Fukamizu A. Arginine methylation of FOXO transcription factors inhibits their phosphorylation by. Akt. Mol. Cell 32 2 (2008) 221-231
31. An W., Kim J., and Roeder R.G. Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 117 6 (2004) 735-748
32. Zhao X., et al. Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity. Genes Dev. 22 5 (2008) 640-653
33. Bakker W.J., Blázquez-Domingo M., Kolbus A., Besooyen J., Steinlein J., Beug H., Coffer P.J., Lowenberg B., von Lindern B., and van Kijk T.B. FoxO3a regulates eyrthroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1. J. Cell Biol. 164 2 (2004) 175-184
34. Blobel G.A. CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood 95 3 (2000) 745-755
35. Kasper L.H., et al. A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis. Nature 419 6908 (2002) 738-743
36. Rebel V.I., et al. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc. Natl. Acad. Sci. U. S. A. 99 23 (2002) 14789-14794
37. Yao T.P., et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93 3 (1998) 361-372
38. Oike Y., et al. Mice homozygous for a truncated form of CREB-binding protein exhibit defects in hematopoiesis and vasculo-angiogenesis. Blood 93 9 (1999) 2771-2779
39. Kung A.L., et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev. 14 3 (2000) 272-277
40. Yang X.J., and Ullah M. MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells. Oncogene 26 37 (2007) 5408-5419
41. Troke P.J., et al. MOZ fusion proteins in acute myeloid leukaemia. Biochem. Soc. Symp. 73 (2006) 23-39
42. Yoshida H., and Kitabayashi I. Chromatin regulation by AML1 complex. Int. J. Hematol. 87 1 (2008) 19-24
43. Kitabayashi I., et al. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J. 17 11 (1998) 2994-3004
44. Aikawa Y., et al. Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation. EMBO J. 25 17 (2006) 3955-3965
45. Wee H.J., et al. PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis. Blood 112 9 (2008) 3777-3787
46. Yamaguchi Y., et al. AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J. Biol. Chem. 279 15 (2004) 15630-15638
47. Nguyen L.A., et al. Physical and functional link of the leukemia-associated factors AML1 and PML. Blood 105 1 (2005) 292-300
48. Hug B.A., and Lazar M.A. ETO interacting proteins. Oncogene 23 24 (2004) 4270-4274
49. Amann J.M., et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol. 21 19 (2001) 6470-6483
50. Lutterbach B., et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol. Cell. Biol. 18 12 (1998) 7176-7184
51. Liu S., et al. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J. Pharmacol. Exp. Ther. 321 3 (2007) 953-960
52. Moldenhauer A., et al. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. J. Leukoc. Biol. 76 3 (2004) 623-633
53. Bird A.P. CpG-rich islands and the function of DNA methylation. Nature 321 6067 (1986) 209-213
54. Okano M., Xie S., and Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat. Genet. 19 3 (1998) 219-220
55. Liu S., et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res. 65 4 (2005) 1277-1284
56. Berg T., et al. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Leuk. Res. 31 4 (2007) 497-506
57. Fazi F., et al. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 12 5 (2007) 457-466
58. Wang J., et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet. 41 1 (2009) 125-129
59. Zhao Q., et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat. Struct. Mol. Biol. 16 3 (2009) 304-311